|Project Title||Principal Investigator||Institution|
|2/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD||King, Bryan||Seattle Children's Hospital|
|3/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD||McCracken, James||University of California, Los Angeles|
|Targeted pharmacologic interventions for autism||McDougle, Christopher||Indiana University-Purdue University Indianapolis|
|1/4-RUPP autism network: Guanfacine for the treatment of hyperactivity in PDD||McDougle, Christopher||Indiana University-Purdue University Indianapolis|
|Mirtazapine treatment of anxiety in children and adolescents with pervasive developmental disorders||McDougle, Christopher||Indiana University|
|4/4-RUPP Autism Network: Guanfacine for the treatment of hyperactivity in PDD||Scahill, Lawrence||Yale University|
|Pharmacotherapy of pervasive developmental disorders||Stigler, Kimberly||Indiana University-Purdue University Indianapolis|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015. |
IACC Recommended Budget: $10,000,000 over 5 years
|N/A ||4.L.C |
|4.L.C. Funding: The recommended budget was partially met.Â |
Progress: A small number (3-7) of studies of pharmacological interventions for co-occurring conditions was funded. There exist many studies examining drugs that are in active use for ADHD that are now being adapted to ADHD-ASD patient groups.
Remaining Gaps, Needs, and Opportunities: There currently is much need for greater understanding of drug efficacy in ASD populations.